Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$4.55 -0.7%	$8.24	$3.80 ▼ $47.80	$7.26M	-1.27	67,203 shs	31,575 shs
BDRX Biodexa Pharmaceuticals	$6.75 +4.5%	$8.33	$5.85 ▼ $160.00	$4M	0.98	33,334 shs	7,675 shs
MDCX Medicus Pharma	$2.45 +20.1%	$2.68	$1.80 ▼ $8.94	$27.69M	N/A	387,297 shs	745,998 shs
TPST Tempest Therapeutics	$9.35 -0.7%	$7.44	$5.33 ▼ $20.67	$41.83M	-1.93	110,562 shs	25,799 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-0.66%	-6.38%	-52.60%	-43.13%	-90.24%
BDRX Biodexa Pharmaceuticals	+4.49%	-4.12%	-25.10%	-41.30%	+674,999,900.00%
MDCX Medicus Pharma	+20.10%	+23.74%	-20.45%	-66.39%	+244,999,900.00%
TPST Tempest Therapeutics	-0.74%	-1.37%	+48.18%	+50.08%	-51.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	3.0591 of 5 stars	3.5	5.0	2.7	1.7	0.0
BDRX Biodexa Pharmaceuticals	0.7282 of 5 stars	0.0	5.0	2.4	0.0	0.0
MDCX Medicus Pharma	1.8612 of 5 stars	3.8	0.0	2.0	0.8	0.0
TPST Tempest Therapeutics	1.3138 of 5 stars	3.3	2.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$31.00	581.32% Upside
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	859.18% Upside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	220.86% Upside

Current Analyst Ratings Breakdown

Latest ACXP, TPST, MDCX, and BDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/12/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$31.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.25 per share	N/A
BDRX Biodexa Pharmaceuticals	$470K	8.90	N/A	N/A	$2.91 per share	2.32
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.24 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$2.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$10.69	N/A	N/A	N/A	N/A	-436.83%	-192.25%	N/A
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
TPST Tempest Therapeutics	-$41.84M	-$14.59	N/A	N/A	N/A	N/A	-334.76%	-130.63%	N/A

Latest ACXP, TPST, MDCX, and BDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ACXP Acurx Pharmaceuticals	-$2.00	-$1.89	+$0.11	-$1.89	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/11/2025	Q2 2025	TPST Tempest Therapeutics	-$3.23	-$2.07	+$1.16	-$2.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	2.38	2.38
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
MDCX Medicus Pharma	N/A	1.29	1.29
TPST Tempest Therapeutics	N/A	2.12	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
BDRX Biodexa Pharmaceuticals	17.51%
MDCX Medicus Pharma	N/A
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	20.30%
BDRX Biodexa Pharmaceuticals	0.34%
MDCX Medicus Pharma	11.20%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	1.58 million	1.26 million	Optionable
BDRX Biodexa Pharmaceuticals	20	620,000	618,000	Not Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
TPST Tempest Therapeutics	20	4.44 million	4.23 million	Optionable

ACXP, TPST, MDCX, and BDRX Headlines

Recent News About These Companies

Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | finanznachrichten.de

Tempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495

August 11, 2025 | quiverquant.comQ

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025 | globenewswire.com

Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment

August 4, 2025 | tipranks.com

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment

July 3, 2025 | tipranks.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - Nasdaq

July 2, 2025 | nasdaq.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China

June 30, 2025 | quiverquant.comQ

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30, 2025 | globenewswire.com

TPST - Tempest Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

TPST Tempest Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11, 2025 | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | quiverquant.comQ

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, TPST, MDCX, and BDRX Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$4.55 -0.03 (-0.66%)

Closing price 08/21/2025 03:59 PM Eastern

Extended Trading

$4.58 +0.03 (+0.66%)

As of 08/21/2025 07:34 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Biodexa Pharmaceuticals NASDAQ:BDRX

$6.75 +0.29 (+4.49%)

Closing price 08/21/2025 03:59 PM Eastern

Extended Trading

$6.48 -0.28 (-4.07%)

As of 08/21/2025 06:01 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Medicus Pharma NASDAQ:MDCX

$2.45 +0.41 (+20.10%)

As of 08/21/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Tempest Therapeutics NASDAQ:TPST

$9.35 -0.07 (-0.74%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$9.26 -0.08 (-0.91%)

As of 08/21/2025 06:55 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time